Numerion Labs
Numerion Labs is an AI-native biotechnology company using a proprietary platform—COSMOS foundation model, APEX hyper-scalable enumerator, and EXPO optimization algorithms—to discover small molecule drug candidates in immune and inflammatory diseases for pharmaceutical partners and its own pipeline.
- Company typePrivate
- Founded2012
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Numerion Labs does
Numerion Labs is an AI-native biotechnology company founded in 2012 and headquartered at 250 Sutter Street in San Francisco, California, with 11–50 employees and Delaware incorporation. The company develops a proprietary AI chemistry superplatform for discovering novel small molecule drug candidates, with a therapeutic focus on immune and inflammatory diseases. Its platform integrates three components: COSMOS, a universal chemistry foundation model for predicting drug function from chemical structure; APEX, a hyper-scalable enumerator that screens 10 billion virtual compounds in under 30 seconds and was co-developed with NVIDIA; and EXPO, expert optimization algorithms that increase the probability of converting novel binders into first- and best-in-class drug candidates. The company claims to operate in a chemical space 10,000 times larger than competitors with 10-billion-fold higher screening efficiency and 100x more efficient model optimization.
Numerion Labs firmographics
Firmographics- Name
- Numerion Labs
- Legal name
- Numerion Labs, Inc.
- Website
- https://numerionlabs.ai
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Numerion Labs is an AI-native biotechnology company using a proprietary platform—COSMOS foundation model, APEX hyper-scalable enumerator, and EXPO optimization algorithms—to discover small molecule drug candidates in immune and inflammatory diseases for pharmaceutical partners and its own pipeline.
- Ownership category
- akta.pro rank
Numerion Labs industry classification
Industry- Product category
- AI Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
Keywords
Where Numerion Labs is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Numerion Labs business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Drug Discovery Partnerships and Licensing: Numerion Labs operates through strategic partnerships with pharmaceutical companies, developing proprietary drug candidates through its AI superplatform for immune and inflammatory diseases. The company appears to be building its own pipeline while also pursuing partnership models typical of AI-native biotech companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Numerion Labs product offering
Product offeringCore offering
Numerion Labs develops and operates an AI superplatform for drug discovery that combines a universal chemistry foundation model (COSMOS), a hyper-scalable virtual compound enumerator (APEX), and expert optimization algorithms (EXPO) to identify novel, drug-like small molecule candidates. The platform powers internal drug programs in immune and inflammatory diseases and is offered to pharmaceutical and biotechnology partners through strategic discovery collaborations.
Product overview
Numerion Labs offers a unified AI superplatform for drug discovery, consisting of three integrated components: COSMOS (Universal Chemistry Foundation Model), APEX (Hyper-scalable Enumerator), and EXPO (Expert Optimization Algorithms). This architecture enables the platform to explore vast chemical space with 10,000x larger chemistry operating domain, 10-billion-fold higher screening efficiency, and 100x more efficient model optimization. The superplatform powers drug programs focused on immune and inflammatory diseases, delivering first- and best-in-class potential small molecule drug candidates.
Differentiator
Problem solved
Functional benefit
Products and services
- AI Drug Hunting Platform An AI-powered superplatform that explores vast chemical space to discover novel, drug-like molecules, integrating the COSMOS universal chemistry foundation model, the APEX hyper-scalable enumerator, and the EXPO expert optimization algorithms. It is offered to pharmaceutical and biotechnology partners to accelerate their small molecule drug discovery pipelines.
- Immune and Inflammatory Disease Programs A pipeline of proprietary drug programs born from the AI superplatform, delivering first- and best-in-class potential in immune and inflammatory diseases. These programs constitute Numerion Labs' own therapeutic pipeline and form the basis for partnership and licensing deals with pharmaceutical companies.
Quantifiable outcome
- 10 billion virtual compounds screened in under 30 seconds
- +3 more outcomes
Companies that use Numerion Labs
Customer profileSegments1 record
Ideal customer profiles1 record
Numerion Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability3 records
Feature3 records
Numerion Labs partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NVIDIAcoreNumerion Labs partnered with NVIDIA to develop and publish breakthrough AI research on ultra-fast screening of hyper-scalable virtual libraries. The APEX Protocol, developed with NVIDIA technology, enables exhaustive evaluation of 10 billion virtual compounds in under 30 seconds, representing a significant advancement in AI-driven drug discovery computational capabilities.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
Numerion Labs competitors and assessment
Company assessmentDirect peers
- BenevolentAI: BenevolentAI uses AI for drug discovery and has a focused pipeline including immune/inflammatory indications, directly comparable to Numerion Labs' therapeutic-area focus and platform-driven approach.
- XtalPi: XtalPi uses AI and large-scale computation for small-molecule drug discovery and crystal-structure prediction, with similar enterprise-pharma discovery partnerships, comparable to Numerion Labs' AI-superplatform approach.
- Exscientia: Exscientia is an AI-native drug discovery company that has advanced multiple candidates into the clinic and signed large pharma collaborations, making it a benchmark for Numerion Labs' platform-to-pipeline trajectory.
- Atomwise: Atomwise uses AI (AtomNet) for structure-based small-molecule drug design and partners with pharma on discovery programs, directly comparable to Numerion Labs' AI platform approach and pharma-licensing business model.
- Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML to discover small molecules across multiple therapeutic areas and has signed large pharma partnerships, making it a direct competitor for both platform deals and pipeline talent.
- Schrödinger: Schrödinger combines physics-based computational chemistry with ML for small-molecule discovery and discovery services, overlapping with Numerion Labs' COSMOS/APEX/EXPO capabilities and pharma customer base.
- Isomorphic Labs: Isomorphic Labs (Alphabet/DeepMind) applies AlphaFold-derived AI to drug discovery and partners with pharma (Novartis, Eli Lilly), representing a well-capitalized, foundation-model-based competitor in the same space as Numerion Labs.
- Insitro: Insitro applies ML to disease modeling and small-molecule discovery and has signed multi-billion-dollar partnerships with pharma (e.g., Bristol Myers Squibb, Eli Lilly), comparable to Numerion Labs' enterprise pharma GTM.
- Iambic Therapeutics: Iambic (formerly Entasis) develops AI-driven small-molecule therapeutics with a foundation-model-based platform, very similar in technology stack and pharma-partnering model to Numerion Labs.
Others
- NVIDIA (BioNeMo / Clara): NVIDIA is both a strategic technology partner and an ecosystem enabler for AI drug discovery via its Clara/BioNeMo offerings, providing the compute stack Numerion Labs' APEX Protocol depends on and competing for the same pharma compute budgets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Numerion Labs social profiles
Digital presenceNumerion Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Numerion Labs leadership team
Management profileNumber of profiles
Profiles1 record
Numerion Labs funding detail
Funding detailFunding overview
Funding rounds11 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Numerion Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Numerion Labs
What does Numerion Labs do?
Numerion Labs develops and operates an AI superplatform for drug discovery that combines a universal chemistry foundation model (COSMOS), a hyper-scalable virtual compound enumerator (APEX), and expert optimization algorithms (EXPO) to identify novel, drug-like small molecule candidates. The platform powers internal drug programs in immune and inflammatory diseases and is offered to pharmaceutical and biotechnology partners through strategic discovery collaborations.
Is Numerion Labs a public or private company?
Numerion Labs is a private company. It is classified as venture growth investor backed and is currently operating.
When was Numerion Labs founded?
Numerion Labs was founded in 2012. It employs 11 to 50 people.
Where is Numerion Labs based?
Numerion Labs is headquartered in San Francisco, United States, in the North America region.
How does Numerion Labs make money?
One revenue line is on record: drug Discovery Partnerships and Licensing.
Who are Numerion Labs's main competitors?
Direct peers on record are BenevolentAI, XtalPi, Exscientia, Atomwise, Recursion Pharmaceuticals, Schrödinger, Isomorphic Labs, Insitro and Iambic Therapeutics. NVIDIA (BioNeMo / Clara) is listed as an others.
Does Numerion Labs have an API?
No public API is recorded for Numerion Labs.
What industry is Numerion Labs in?
Numerion Labs's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.